Pathogen-specific bacterial DNA sequences in Escherichia coli genomes

Pathogen-specific bacterial DNA sequences in Escherichia coli genomes serve as the molecular targets for precision antimicrobial therapies utilizing the CRISPR-Cas3 system (Gomaa et al., 2014). Unlike the more common Cas9 system which creates single double-strand breaks, Cas3 functions as a processive helicase-nuclease that moves along the DNA, creating large-scale deletions and effectively shredding the bacterial genome (Selle et al., 2020). This extensive damage is irreparable by the bacterial cell's repair mechanisms, leading to rapid and selective cell death. This targeting strategy is particularly relevant for treating multidrug-resistant infections, such as those caused by uropathogenic E. coli (UPEC) in urinary tract infections (ClinicalTrials.gov, NCT03851211). By delivering the CRISPR-Cas3 machinery via engineered bacteriophages, these specific DNA sequences can be targeted with high precision, minimizing collateral damage to the commensal microbiome (Locus Biosciences, 2024). This approach represents a significant shift from traditional antibiotics, focusing on the degradation of the pathogen's genetic core rather than inhibiting metabolic pathways. The specificity of the guide RNA ensures that only bacteria carrying the exact target sequence are eliminated, providing a highly tailored therapeutic intervention.

Other names

E. coli genomic DNAPathogenic E. coli DNA sequencesCRISPR-Cas3 target sequencesUropathogenic Escherichia coli DNA

CRISPR-Cas3 mediated processive DNA degradation and genomic shredding leading to bacterial cell death.